{"transactions":[{"id":3755600,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2018-11-21T21:50:39.000Z","date":"2018-10-08","kind":"grant","acquired":true,"shares":144000,"price":1.38,"value":198720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."}],"balance_after":1056474,"source":{"system":"sec-edgar","filing":"0001615774-18-013143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577418013143/ownership.xml","form_type":"4/A","original_submission_date":"2018-11-20"}},{"id":3757955,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2018-11-20T22:46:39.000Z","date":"2018-10-08","kind":"grant","acquired":true,"shares":144000,"price":1.38,"value":198720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person."}],"balance_after":1056474,"source":{"system":"sec-edgar","filing":"0001615774-18-013075","document":"s114146_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577418013075/s114146_form4.xml","form_type":"4"}},{"id":3797514,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2018-10-04T22:33:55.000Z","date":"2018-10-03","kind":"grant","acquired":true,"shares":270270,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reporting Person purchased 270,270 units at a price of $1.85 per unit, with each unit consisting of (i) one share of Common Stock and (ii) one Common Stock Purchase Warrant to purchase one share of Common Stock for $2.00 per share."}],"balance_after":270270,"derivative":{"exercise_price":2,"exercise_date":"2019-03-24","expiration_date":"2023-09-23","underlying":"Common Stock","underlying_shares":270270},"source":{"system":"sec-edgar","filing":"0001615774-18-010497","document":"s113137_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577418010497/s113137_form4.xml","form_type":"4"}},{"id":3797513,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2018-10-04T22:33:55.000Z","date":"2018-10-03","kind":"grant","acquired":true,"shares":270270,"price":1.85,"value":499999.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"270,270 shares of Common Stock and Warrants to purchase 270,270 shares of Common Stock for $2.00 were purchased by the Reporting Person for an aggregate of $499,999.50 pursuant to a Subscription Agreement, dated September 21, 2018 (the \"Subscription Agreement\"), between the Issuer and the investors party thereto."}],"balance_after":912474,"source":{"system":"sec-edgar","filing":"0001615774-18-010497","document":"s113137_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577418010497/s113137_form4.xml","form_type":"4"}},{"id":3914653,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-31T00:30:02.000Z","date":"2018-05-25","kind":"grant","acquired":true,"shares":4500,"price":2.27,"value":10215.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 25, 2018, the Board of Directors (the \"Board\") of MYnd Analytics, Inc. granted the indicated number of restricted shares (the \"Shares\") in lieu of the remaining amount of Michal Votruba's Board fee for the 2017-2018 fiscal year. Mr. Votruba has agreed to assign all compensation provided for his service on the Board to the Reporting Person. The Shares were issued pursuant to the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan."}],"balance_after":642204,"source":{"system":"sec-edgar","filing":"0001615774-18-004584","document":"s110528_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577418004584/s110528_form4.xml","form_type":"4"}},{"id":4203715,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-09-22T23:03:06.000Z","date":"2017-09-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal quarterly installments beginning on December 19, 2017."}],"balance_after":12000,"derivative":{"exercise_price":3.6,"expiration_date":"2027-09-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001615774-17-005313","document":"s107587_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577417005313/s107587_form4.xml","form_type":"4"}},{"id":4203714,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-09-22T23:03:06.000Z","date":"2017-09-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":637704,"source":{"system":"sec-edgar","filing":"0001615774-17-005313","document":"s107587_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577417005313/s107587_form4.xml","form_type":"4"}},{"id":4375535,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2017-03-23T01:19:19.000Z","date":"2017-03-20","kind":"purchase","acquired":true,"shares":160000,"price":6.25,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired by the Reporting Person in a private placement of securities by the Issuer."}],"balance_after":625704,"source":{"system":"sec-edgar","filing":"0001615774-17-001188","document":"s105639_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577417001188/s105639_form4.xml","form_type":"4"}},{"id":4568683,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Investments SICAV a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2016-11-03T21:28:32.000Z","date":"2016-11-01","kind":"other","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock, par value $0.001 per share (the \"Common Stock\") of MYnd Analytics, Inc. (the \"Issuer\") were initially granted by the Issuer to Michal Votruba, a director of the Issuer and an employee of the Reporting Person. The grant was recommended by the Issuer's compensation committee and approved by the Issuer's board of directors on September 22, 2016 under the Amended and Restated 2012 Omnibus Incentive Compensation Plan (the \"Plan\"), subject to stockholder approval of the Plan, and was subsequently made on November 1, 2016 when the Issuer's stockholders approved the Plan. Upon grant on November 1, 2016, the shares were immediately assigned and issued directly to the Reporting Person for no consideration, pursuant to a binding verbal agreement between Mr. Votruba and the Reporting Person."}],"balance_after":465704,"source":{"system":"sec-edgar","filing":"0001615774-16-008017","document":"s104542_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416008017/s104542_form4.xml","form_type":"4"}},{"id":4596746,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."}],"balance_after":0,"derivative":{"exercise_date":"2016-09-19","expiration_date":"2016-09-19","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596745,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":15000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."}],"balance_after":5000000,"derivative":{"exercise_date":"2016-09-19","expiration_date":"2016-09-19","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596744,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":22000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."}],"balance_after":20000000,"derivative":{"exercise_date":"2016-09-19","expiration_date":"2016-09-19","underlying":"Common Stock","underlying_shares":22000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596743,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"exercise","acquired":false,"reported_value":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.025,"underlying":"Common Stock","underlying_shares":10000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596742,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"exercise","acquired":false,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.025,"underlying":"Common Stock","underlying_shares":30000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596741,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"exercise","acquired":false,"reported_value":350000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.025,"underlying":"Common Stock","underlying_shares":12000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596740,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"exercise","acquired":false,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.025,"underlying":"Common Stock","underlying_shares":30000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596739,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."}],"balance_after":42000000,"derivative":{"exercise_price":0.05,"exercise_date":"2016-09-19","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596738,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"shares":15000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."}],"balance_after":37000000,"derivative":{"exercise_price":0.05,"exercise_date":"2016-09-19","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596737,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"shares":22000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes."}],"balance_after":22000000,"derivative":{"exercise_price":0.05,"exercise_date":"2016-09-19","underlying":"Common Stock","underlying_shares":22000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596736,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."}],"balance_after":0,"derivative":{"exercise_price":0.05,"exercise_date":"2016-08-09","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596735,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":15000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."}],"balance_after":5000000,"derivative":{"exercise_price":0.05,"exercise_date":"2015-12-28","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596734,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"shares":22000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"See Exhibit 99.2."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"See Exhibit 99.2."}],"balance_after":20000000,"derivative":{"exercise_price":0.05,"exercise_date":"2015-12-23","underlying":"Common Stock","underlying_shares":22000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596733,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"reported_value":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"See Exhibit 99.1."},{"field":"reported_value","element":"transactionTotalValue","label":"F5","text":"See Exhibit 99.1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"expiration_date":"2017-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596732,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"See Exhibit 99.1."},{"field":"reported_value","element":"transactionTotalValue","label":"F5","text":"See Exhibit 99.1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"expiration_date":"2017-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596731,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"reported_value":350000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"See Exhibit 99.1."},{"field":"reported_value","element":"transactionTotalValue","label":"F5","text":"See Exhibit 99.1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"expiration_date":"2017-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596730,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"purchase","acquired":true,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"See Exhibit 99.1."},{"field":"reported_value","element":"transactionTotalValue","label":"F5","text":"See Exhibit 99.1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"expiration_date":"2017-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596729,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"reported_value":250000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"The 5% secured convertible notes in the amounts of $750,000 and $250,000, the amendments of which are reported in this Form 4, were initially issued by the Issuer on December 28, 2015 and August 9, 2016, respectively. As previously reported, on December 28, 2015, the Issuer issued the 5% secured convertible promissory notes in the amount of $750,000 pursuant to the Second Amended and Restated Note Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein as later amended (the \"A&R Note & Warrant Agreement\"). Additionally, on August 9, 2016, the Issuer issued the 5% secured convertible promissory notes in the amount of $250,000 under the A&R Note Warrant Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596728,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"The 5% secured convertible notes in the amounts of $750,000 and $250,000, the amendments of which are reported in this Form 4, were initially issued by the Issuer on December 28, 2015 and August 9, 2016, respectively. As previously reported, on December 28, 2015, the Issuer issued the 5% secured convertible promissory notes in the amount of $750,000 pursuant to the Second Amended and Restated Note Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein as later amended (the \"A&R Note & Warrant Agreement\"). Additionally, on August 9, 2016, the Issuer issued the 5% secured convertible promissory notes in the amount of $250,000 under the A&R Note Warrant Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596727,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"reported_value":350000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The 5% secured convertible notes in the amount of $350,000, the amendment of which is reported in this Form 4, were initially issued by the Issuer on September 24, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":7000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596726,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"other","acquired":false,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The 5% secured convertible notes in the amount of $750,000, the amendment of which is reported in this Form 4, were initially issued by the Issuer on September 26, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"See Exhibit 99.1."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4596725,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2016-09-23T20:52:47.000Z","date":"2016-09-19","kind":"exercise","acquired":true,"shares":444454,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 19, 2016, MYnd Analytics, Inc. (the \"Issuer\") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2016, MYnd Analytics, Inc. (the \"Issuer\") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 19, 2016, MYnd Analytics, Inc. (the \"Issuer\") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up)."}],"balance_after":445704,"source":{"system":"sec-edgar","filing":"0001615774-16-007343","document":"s104203_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007343/s104203_form4.xml","form_type":"4"}},{"id":4602887,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-15T20:27:50.000Z","date":"2016-08-09","kind":"purchase","acquired":true,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Notes and warrant to purchase shares of Common Stock were issued in exchange for $250,000 in cash pursuant to the A&R Note & Warrant Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of the warrants to purchase shares of Common Stock is the earlier of (i) December 31, 2020 and (ii) the date that is 45 days following the date on which the daily closing price of the Issuer's shares of Common Stock listed on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Issuer's Common Stock is traded or listed) exceeds $0.25 for at least ten consecutive trading days."}],"balance_after":42000000,"derivative":{"exercise_price":0.05,"exercise_date":"2016-08-09","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007204","document":"s104129_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007204/s104129_form4.xml","form_type":"4"}},{"id":4602886,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-15T20:27:50.000Z","date":"2016-08-09","kind":"purchase","acquired":true,"reported_value":250000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The 5% secured convertible promissory notes (the \"Notes\") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the \"A&R Note & Warrant Agreement\"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and\ncertain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity."},{"field":"reported_value","element":"transactionTotalValue","label":"F3","text":"The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Notes and warrant to purchase shares of Common Stock were issued in exchange for $250,000 in cash pursuant to the A&R Note & Warrant Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Notes are convertible into shares of Common Stock (i) automatically upon the closing of a qualified equity offering with total proceeds of at least $5 million, at a conversion price of $0.05 per share, or (ii) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 5% secured convertible promissory notes (the \"Notes\") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the \"A&R Note & Warrant Agreement\"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and\ncertain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F9","text":"As of September 15, 2016, consists of Notes in aggregate principal amounts of $750,000 issued on September 26, 2014, $350,000 issued on September 24, 2015, $750,000 issued on December 28, 2015 and $250,000 issued on August 9, 2016."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007204","document":"s104129_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007204/s104129_form4.xml","form_type":"4"}},{"id":4602885,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2016-09-15T20:27:50.000Z","date":"2015-12-28","kind":"purchase","acquired":true,"shares":15000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Notes and warrant to purchase shares of Common Stock were issued in exchange for $750,000 in cash pursuant to the A&R Note & Warrant Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of the warrants to purchase shares of Common Stock is the earlier of (i) December 31, 2020 and (ii) the date that is 45 days following the date on which the daily closing price of the Issuer's shares of Common Stock listed on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Issuer's Common Stock is traded or listed) exceeds $0.25 for at least ten consecutive trading days."}],"balance_after":37000000,"derivative":{"exercise_price":0.05,"exercise_date":"2015-12-28","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007204","document":"s104129_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007204/s104129_form4.xml","form_type":"4"}},{"id":4602884,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Secured Convertible Note due December 2017","published_at":"2016-09-15T20:27:50.000Z","date":"2015-12-28","kind":"purchase","acquired":true,"reported_value":750000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The 5% secured convertible promissory notes (the \"Notes\") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the \"A&R Note & Warrant Agreement\"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and\ncertain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity."},{"field":"reported_value","element":"transactionTotalValue","label":"F3","text":"The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Notes and warrant to purchase shares of Common Stock were issued in exchange for $750,000 in cash pursuant to the A&R Note & Warrant Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Notes are convertible into shares of Common Stock (i) automatically upon the closing of a qualified equity offering with total proceeds of at least $5 million, at a conversion price of $0.05 per share, or (ii) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 5% secured convertible promissory notes (the \"Notes\") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the \"A&R Note & Warrant Agreement\"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and\ncertain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes."}],"derivative":{"exercise_price":0.05,"expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":15000000},"source":{"system":"sec-edgar","filing":"0001615774-16-007204","document":"s104129_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007204/s104129_form4.xml","form_type":"4"}},{"id":4602883,"issuer":{"id":205,"kind":"organization","name":"Emmaus Life Sciences, Inc.","symbol":"EMMA"},"owners":[{"id":162270,"kind":"organization","name":"RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.","position":1,"cik":"0001682250","reported_name":"RSJ Private Equity Investment Fund with variable registered capital, a.s.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2016-09-15T20:27:50.000Z","date":"2016-04-05","kind":"other","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock, par value $0.001 per share (the \"Common Stock\") of MYnd Analytics, Inc. (the \"Issuer\") were granted by the Issuer to Michal Votruba, a director of the Issuer and an employee of Reporting Person, on April 5, 2016. Upon grant, the shares were immediately assigned to the Reporting Person for no consideration, pursuant to a binding verbal agreement between Mr. Votruba and the Reporting Person."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0001615774-16-007204","document":"s104129_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822370/000161577416007204/s104129_form4.xml","form_type":"4"}}]}